NCT02699957 Left Atrial Appendage Occlusion Registry (LAAO Registry)
| NCT ID | NCT02699957 |
| Status | Recruiting |
| Phase | — |
| Sponsor | American College of Cardiology |
| Condition | Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2015-12 |
| Primary Completion | 2029-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2015-12 with a primary completion date of 2029-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Left Atrial Appendage Occlusion Registry (LAAO Registry™) is designed to assess the prevalence, demographics, management, and outcomes of patients undergoing percutaneous and epicardial based left atrial appendage occlusion procedures to reduce the risk of stroke. Patient-level data will be submitted by participating hospitals on a quarterly basis to the American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR). The primary aims of the LAAO Registry are to optimize the outcomes and management of patients through the implementation of evidence-based guideline recommendations in clinical practice, facilitate efforts to improve the quality and safety for patients undergoing percutaneous and epicardial based left atrial appendage procedures, investigate novel quality improvement methods and provide risk-adjusted assessment of patients for comparison with nationwide NCDR data. The secondary purpose of the LAAO Registry is to serve as a rich source of clinical data to support assessments of short- and long-term safety, comparative and cost effectiveness research, and as a scalable data infrastructure for post market studies.
Eligibility Criteria
Inclusion Criteria: * Adult patients, 18 years and older, undergoing percutaneous or epicardial left atrial appendage occlusion procedures Exclusion Criteria: * None
Contact & Investigator
Paul Varosy, MD
STUDY CHAIR
VA Eastern Colorado Health Care System
Frequently Asked Questions
Who can join the NCT02699957 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02699957 currently recruiting?
Yes, NCT02699957 is actively recruiting participants. Contact the research team at mfox@acc.org for enrollment information.
Where is the NCT02699957 trial being conducted?
This trial is being conducted at Washington D.C., United States.
Who is sponsoring the NCT02699957 clinical trial?
NCT02699957 is sponsored by American College of Cardiology. The principal investigator is Paul Varosy, MD at VA Eastern Colorado Health Care System. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.